QS Pharma, LLC

QS Pharma, LLC specializes in drug development, focusing on innovative manufacturing solutions that enhance the efficiency and effectiveness of the pharmaceutical process. Founded in 2002, QS Pharma, LLC is based in Boothwyn, US, and operates within the pharmaceutical sector, providing specialized drug development services. In February 2017, QS Pharma was acquired by Quotient Clinical, a portfolio company of GHO Capital, from Charles River Laboratories, Inc. This acquisition marked a strategic pivot in its business operations.

QS Pharma offers an integrated suite of drug development services, including formulation development, clinical trial manufacturing, and commercial drug product manufacturing. The company utilizes its proprietary Translational Pharmaceutics® platform to ensure real-time cGMP manufacturing, facilitating a smooth transition from preclinical phases to commercial supply. QS Pharma caters to a wide range of clients in North America and Europe, particularly in therapeutic areas such as oncology, neurology, and rare diseases. Revenue is primarily generated through partnerships with pharmaceutical and biotechnology companies, engaging in business-to-business transactions that include both fixed and bundled pricing models.

The company’s offerings, notably the Translational Pharmaceutics® platform, are critical to its revenue generation, enhancing client development timelines and reflecting a robust market presence. Looking ahead, QS Pharma plans to launch new products and expand into additional international markets. The company aims to leverage its recent acquisition by Quotient Clinical to enhance its service offerings and operational capabilities. The acquisition is expected to facilitate greater market penetration and operational synergies, although specific launch dates for new products or targeted regions for market expansion have not been disclosed.